Volume 124, Issue 6 , Pages 1311-1318.e7, December 2009
ORAI1 deficiency and lack of store-operated Ca2+ entry cause immunodeficiency, myopathy, and ectodermal dysplasia
Background
Defects in the development or activation of T cells result in immunodeficiency associated with severe infections early in life. T-cell activation requires Ca2+ influx through Ca2+-release activated Ca2+ (CRAC) channels encoded by the gene ORAI1.
Objective
Investigation of the genetic causes and the clinical phenotype of immunodeficiency in patients with impaired Ca2+ influx and CRAC channel function.
Methods
DNA sequence analysis for mutations in the genes ORAI1, ORAI2, ORAI3, and stromal interaction molecule (STIM) 1 and 2, as well as mRNA and protein expression analysis of ORAI1 in immunodeficient patients. Immunohistochemical analysis of ORAI1 tissue distribution in healthy human donors.
Results
We identified mutations in ORAI1 in patients from 2 unrelated families. One patient is homozygous for a frameshift nonsense mutation in ORAI1 (ORAI1-A88SfsX25), and a second patient is compound heterozygous for 2 missense mutations in ORAI1 (ORAI1-A103E/L194P). All 3 mutations abolish ORAI1 expression and impair Ca2+ influx and CRAC channel function. The clinical syndrome associated with ORAI1 deficiency is characterized by immunodeficiency with a defect in the function but not in the development of lymphocytes, congenital myopathy, and anhydrotic ectodermal dysplasia with a defect in dental enamel calcification. In contrast with the limited clinical phenotype, we found ORAI1 protein expression in a wide variety of cell types and organs.
Conclusion
Ca2+ influx through ORAI1 is crucial for lymphocyte function in vivo. Despite almost ubiquitous ORAI1 expression, the channel has a nonredundant role in only a few cell types judging from the limited clinical phenotype in ORAI1-deficient patients.
Key words: ORAI1, STIM1, CRAC, calcium channel, Ca2+, store-operated Ca2+ entry, T cells, immunodeficiency, signal transduction, congenital myopathy, anhydrotic ectodermal dysplasia, dental enamel, amelogenesis imperfecta
Abbreviations used: CRAC, Ca2+ release activated Ca2+, EDA, Ectodermal dysplasia with anhydrosis, HSCT, Hematopoietic stem cell transplantation, NK, Natural killer, SCID, Severe combined immunodeficiency, SNP, Single nucleotide polymorphism, SOCE, Store-operated Ca2+ entry, STIM, Stromal interaction molecule
Supported by National Institutes of Health grants (S.F., A.R.), a March of Dimes Foundation grant (S.F.), and an INSERM grant (A.F.).
Disclosure of potential conflict of interest: T. Kawasaki receives research support through the Uehara Postdoctoral Fellowship. J. Kirschner has received research support from the Muscular Dystrophy Network and the TREAT-NMD Network. A. Rao is a founder and advisor of CalciMedica and has received research support from the National Institutes of Health, JDRF, and GlaxoSmithKline. A. Fischer is a contractor for INSERM, the French National Research Agency, and the European Community. S. Feske is a founder and advisor of CalciMedica and has received research support from the National Institutes of Health/National Institute of Allergy and Infectious Diseases, the March of Dimes Foundation, and the Charles Hood Foundation. The rest of the authors have declared that they have no conflict of interest.
PII: S0091-6749(09)01533-4
doi:10.1016/j.jaci.2009.10.007
© 2009 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Volume 124, Issue 6 , Pages 1311-1318.e7, December 2009
